| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we tried to develop a new method by which autoimmune diseases can be cured using a monoclonal T cells with single antigen specificity. It has been reported that the monoclonal helper T cells expressing TCR (R7-39) specific for target antigen originally identified as a causative antigen of arthritis and dermatitis in skg mouse. Therefore, in this study, we produced regulatory T cells (Treg) that monoclonally express TCR (R7-39) and tested whether these cells exert therapeutic effect on the desiase model described above. We found that, although adaptive transfer of these cells were not effective for arthritis, these cells showed efficacy in reducing the severity of dermatitis. This can be said as a first demonstration in the world that showed treatment of disease by using Treg. Some planned experiments were not necessarily completed as originally designed, but we can say that a significant results were obtained during the study period.
|
